For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
The purpose of this study is to test the safety of a CAR-T (chimeric antigen receptor T cell) therapy. This study tests different doses of the new cell therapy in alveolar soft part sarcoma, renal cancer and breast cancer tumours to see which dose is safest for people.
The purpose of this study is to compare the effects on you and your prostate cancer of a new drug compared to other drugs which are the current standard treatment to treat this disease.
The purpose of this study is to determine whether a blood test can help us make better decisions about who should get immunotherapy after surgery for bladder cancer and which immunotherapy treatment is best.
The study will investigate a new test which can detect bladder cancer DNA in the blood. This is important because this test might indicate the presence of bladder cancer cells somewhere in the body, even if cancer can’t be seen on a scan of the body.
The purpose of this study is to compare the effects on you and your prostate cancer of a new drug compared to other drugs which are the current standard treatment for this disease. The addition of the new drug to standard treatment could prevent your prostate cancer from progressing, but this cannot be known for sure. This study will help doctors find out if this different approach is better than the usual one.
The purpose of this study is to compare the effects on you and your prostate cancer of getting a higher dose of radiation therapy given over a shorter period of time compared to the current way radiation therapy is used to treat prostate cancer.
The purpose of this study is to see if adding a new drug to other drugs which are commonly used to treat metastatic urothelial cancer is better than the commonly used drugs alone.
